Patient
SITE006-0059
completed Phase IIIA Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · SITE006 (GBR) (Dr. Rossi)
consented 2025-11-02
Adverse events
9
Serious AEs
1
Open data queries
0
Luna dropout signal
—
not on Luna
Adverse events 9
Grade 3 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2022-12-28 (study day 227); relationship: RELATED
Grade 3 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2022-12-12 (study day 211); relationship: not assessed
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-11-04 (study day 173); relationship: RELATED
Grade 2 Asthenia — outcome: RECOVERED/RESOLVED; onset 2022-10-16 (study day 154); relationship: not assessed
Grade 3 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-09-27 (study day 135); relationship: not assessed
Grade 1 Constipation — outcome: RECOVERED/RESOLVED; onset 2022-08-21 (study day 98); relationship: NOT RELATED
Grade 2 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2022-07-26 (study day 72); relationship: NOT RELATED
Grade 1 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2022-07-14 (study day 60); relationship: not assessed
Grade 4 Adrenal insufficiency — outcome: RECOVERED/RESOLVED; onset 2022-07-01 (study day 47); relationship: not assessed; serious criteria: life-threatening
Data queries 0
No data queries
The CDM sweep raises queries on inconsistent fields.
Luna engagement
This participant doesn't use Luna
Invite them from the site to track mood, adherence and check-ins.